Efficacy and Safety of Isa-KRd Induction Before Response-Adapted Consolidation in Transplant Eligible Newly Diagnosed Multiple Myeloma: an Interim Analysis of the IFM2020-02 MIDAS Study

被引：0

作者：

Perrot, Aurore ^{[1
]}

Touzeau, Cyrille ^{[2
]}

Lambert, Jerome ^{[3
]}

Hulin, Cyrille ^{[4
]}

Caillot, Denis ^{[5
]}

Karlin, Lionel ^{[6
]}

Arnulf, Bertrand ^{[7
]}

Rey, Philippe ^{[8
]}

Garderet, Laurent ^{[9
]}

Macro, Margaret ^{[10
]}

Escoffre-Barbe, Martine

Gay, Julie

Basque, C. H. Cote

Chalopin, Thomas ^{[11
]}

Belhadj, Karim ^{[12
]}

de Colella, Jean Marc Schiano ^{[13
]}

Tiab, Mourad ^{[14
]}

Mohty, Mohamad ^{[15
,16
]}

Kuhnowski, Frederique ^{[17
]}

Fontan, Jean ^{[18
]}

Manier, Salomon ^{[19
]}

Orsini-Piocelle, Frederique ^{[20
]}

Vincent, Laure ^{[21
]}

Leleu, Xavier ^{[22
]}

Corre, Jill ^{[23
]}

Moreau, Philippe ^{[24
]}

机构：

[1] Ctr Hosp Univ Toulouse, Serv Hematol, Toulouse, France

[2] Ctr Hosp Univ Nantes, Nantes, France

[3] Hop St Louis, Paris, France

[4] Univ Hosp, Dept Hematol, Hop Haut Leveque, Pessac, France

[5] CHU Dijon, Dijon, France

[6] Ctr Hosp Lyon Sud, Pierre Benite, France

[7] Univ Paris Cite, St Louis Hosp, AP HP, Paris, France

[8] Lyon Unicanc, Lyon, France

[9] Hop La Pitie Salpetriere, Paris, France

[10] Ctr Hosp Univ CHU Caen, Caen, France

[11] Tours Univ Hosp, Dept Hematol & Cell Therapy, Tours, France

[12] Hop Henri Mondor, Hematol, Creteil, France

[13] Paoli Calmettes Inst, Marseille, France

[14] CHD La Roche sur Yon, La Roche Sur Yon, France

[15] Sorbonne Univ, Hop St Antoine, Paris, France

[16] INSERM, UMRS938, Paris, France

[17] Inst Curie, Paris, France

[18] CHU Besancon, Besancon, France

[19] Univ Hosp Ctr Lille, Dept Hematol, Lille, France

[20] CH Annecy, Annecy, France

[21] Ctr Hosp Univ Montpellier, Dept Hematol Clin, Montpellier, France

[22] CHU Poitiers, PRC, Hematol, Poitiers, France

[23] IUC T Oncopole, Unite Genom Myelome, Toulouse, France

[24] Univ Hosp Hotel Dieu, Hematol Dept, Paris, France

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA-54

引用

页码：S34 / S35

页数：2

共 13 条

[1] Carfilzomib, lenalidomide and dexamethasone (KRd) versus elotuzumab-KRd as induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma: post-induction IMWG and MRD response of a randomized multicenter study
Knop, S.
Kull, M.
Kroenke, J.
Drewniok, P.
Schaefer-Eckart, K.
von, Metzler I.
Wolleschak, D.
Kimmig, C.
Greiner, J.
Boettcher, S.
Dechow, T.
Hentrich, M.
Khandanpour, C.
Shumilov, E.
Naumann, R.
Seggewiss-Bernhardt, R.
Hackanson, B.
Wang, S. -Y.
Salwender, H.
Sormann, S.
Stuebig, T.
Brueggemann, M.
Einsele, H.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 58 - 59
[2] Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Costa, Luciano J.
Chhabra, Saurabh
Godby, Kelly N.
Medvedova, Eva
Cornell, Robert F.
Hall, Aric C.
Silbermann, Rebecca W.
Innis-Shelton, Racquel
Dhakal, Binod
DeIdiaquez, Diego
Hardwick, Pamela
Biru, Yelak
Omel, James L.
Hari, Parameswaran
Callander, Natalie Scott
BLOOD, 2019, 134
[3] Response-adapted sequential Azacitidine and induction chemotherapy in patients > 60 years with newly diagnosed AML eligible for chemotherapy: Interim analysis of the DRKS00004519 study (RAS-AZIC)
Jaekel, N.
Hubert, K.
Krahl, R.
Haenel, M.
Maschmeyer, G.
Herbst, R.
Jacob, C.
Schulze, S.
Wang, S. -Y
Cross, M.
Brosteanu, O.
Niederwieser, D.
Al-Ali, H. K.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 44 - 44
[4] Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study
Knop, Stefan
Stuebig, Thomas
Kull, Miriam
Greil, Richard
Steiner, Normann
Bassermann, Florian
Nogai, Axel
von Lilienfeld-Toal, Marie
Janjetovic, Snjezana
Trautmann-Grill, Karolin
Bittrich, Max
Engelhardt, Monika Martha
Hoferer, Anette
Theurich, Sebastian
Binder, Mascha
Zojer, Niklas
Duerk, Heinz A.
Brueggemann, Monika
Held, Swantje
Einsele, Hermann
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[5] RESPONSE-ADAPTED SEQUENTIAL AZACITIDINE AND INDUCTION CHEMOTHERAPY IN PATIENTS >60 YEARS OLD WITH NEWLY DIAGNOSED AML ELIGIBLE FOR CHEMOTHERAPY (RAS-AZIC): INTERIM ANALYSIS OF THE DRKS00004519 STUDY
Jaekel, N.
Hubert, K.
Krahl, R.
Haenel, M.
Maschmeyer, G.
Herbst, R.
Jakob, C.
Schulze, S.
Wang, S. Y.
Cross, M.
Brosteanu, O.
Niederwieser, D.
Al-Ali, H. K.
HAEMATOLOGICA, 2016, 101 : 326 - 327
[6] QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study
Ludwig, Heinz
Melchardt, Thomas
Schweitzer, Ilvy
Sormann, Siegfried
Schreder, Martin
Andel, Johannes
Hartmann, Bernd
Zojer, Niklas
Schoeffmann, Laurenz
Gunsilius, Eberhard
Podar, Klaus
Egle, Alexander
Willenbacher, Wolfgang
Woell, Ewald
Ruckser, Reinhard
Bozic, Boris
Krauth, Maria-Theresa
Petzer, Andreas
Schmitt, Clemens
Machherndl-Spandl, Sigrid
Agis, Hermine
Fillitz, Michael
Wang, Song-Yau
Knop, Stefan
Greil, Richard
EJHAEM, 2024, 5 (03): : 494 - 504
[7] Interim Analysis of Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma.
Ishida, Tadao
Kimura, Hideo
Kubo, Koumei
Sunami, Kazutaka
Ozaki, Shuji
Takezako, Naoki
Handa, Hiroshi
Kosugi, Hiroshi
Murakami, Hirokazu
Shimizu, Kazuyuki
BLOOD, 2015, 126 (23)
[8] Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myelome (IFM)
Perrot, Aurore
Lauwers-Cances, Valerie
Touzeau, Cyrille
Decaux, Olivier
Hulin, Cyrille
Macro, Magaret
Stoppa, Anne-Marie
Chretien, Marie Lorraine
Karlin, Lionel
Mariette, Clara
Jacquet, Caroline
Roussel, Murielle
Guillemot, Coralie
Devlamynck, Laure
Avet-Loiseau, Herve
Moreau, Philippe
Attal, Michel
BLOOD, 2021, 138
[9] Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)
Ninkovic, Slavisa
Murphy, Nicholas E.
Sidiqi, Hasib
Wallington-Beddoe, Craig Thomas
Puliyayil, Anish
Yannakou, Costas K.
Janowski, Wojt
Yuen, Flora
Spencer, Andrew
Quach, Hang
BLOOD, 2021, 138
[10] Twice-weekly induction with ixazomib-lenalidomide-dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant-eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014-03
Perrot, Aurore
Roussel, Murielle
Lauwers-Cances, Valerie
Hulin, Cyrille
Leleu, Xavier
Touzeau, Cyrille
Facon, Thierry
Mariette, Clara
Schiano, Jean-Marc
Gay, Julie
Montes, Lydia
Ranta, Dana
Huguet, Amandine
Wuilleme, Soraya
Dejoie, Thomas
Devlamynck, Laure
Corre, Jill
Avet-Loiseau, Herve
Moreau, Philippe
Attal, Michel
BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (03) : 891 - 899

← 1 2 →